• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief

N/A
N/A
Protected

Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Copied!
2
0
0

Pełen tekst

(1)

1

The Voice of the Editor-in-Chief

That is one thing you can be sure of in life: Things change. And so, since May 2019, after the 20th Scien- tific Congress of Diabetes Poland in Lublin, our Society has been managed by a new Main Board and a new President. And now the time has come for a new Editor- -in-Chief of “Clinical Diabetology”. Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science database and in the Ministry of Science and Higher Education list of scored journals. Step by step, it is get- ting closer to the PubMed database, which in turn will increase the chance of obtaining the impact factor (IF).

Starting from this issue, the honor and obligation to direct the journal falls on the shoulders of the under- signed. I will of course continue the efforts of previous Editor-in-Chief. I would like “Clinical Diabetology” to develop further, in terms of content enrichment, edi- torial structure, number of sections, contact with our readers, and current topics. Together with the renewed Editorial Team, we will try to respond quickly to what is happening in diabetology (and a lot is happening at the moment), so that everyone interested in our favorite field can immediately understand the changes in the science of pathophysiology, diagnosis and treatment of diabetes and its complications. Of course, the jour-

nal will remain a bimonthly, but we will dynamically comment on the latest research and publish scientific papers and review articles addressing the most current problems of modern diabetology.

The coming time will be special. In 2021, it will be 100 years from the discovery of insulin, and in January 2022, 100 years will pass from its first documented use in humans. It will be an opportunity not only to celebrate the anniversary of one of the most impor- tant events in the history of medicine, but above all to broaden social impact and build awareness about diabetes and the need to conduct research on this disease. We are convinced that “Clinical Diabeto- logy” will be the scientific and social medium in this celebration, serving to and strengthening Polish and European diabetology.

However, the most important thing for each and every journal are the readers. We hope that you will very actively participate in developing “Clinical Diabe- tology”, not only by reading published materials, but also by submitting your papers, letters, comments, articles, as well as sending suggestions what we sho- uld do to improve the journal, thereby supporting the development of diabetology in our country. On behalf of the Editorial Team, I promise to do our best to accomplish this task.

Editor-in-Chief

Prof. Leszek Czupryniak

Dear Colleagues,

Dear Readers,

(2)

Cytaty

Powiązane dokumenty

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would